Cita APA (7a ed.)
Albach, F., Wagner, F., Hüser, A., Igel, J., Joseph, D., Hilbert, J., . . . Steffgen, J. (2018). Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: A potential novel treatment for autoimmune diseases. European Journal of Clinical Pharmacology, 74(2), 161-170.
Cita Chicago Style (17a ed.)
Albach, Fredrik, Frank Wagner, Andreas Hüser, Julia Igel, David Joseph, James Hilbert, Corinna Schoelch, Steven Padula, y Jürgen Steffgen. "Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases." European Journal of Clinical Pharmacology 74, no. 2 (2018): 161-170.
Cita MLA (9a ed.)
Albach, Fredrik, et al. "Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases." European Journal of Clinical Pharmacology, vol. 74, no. 2, 2018, pp. 161-170.
Precaución: Estas citas no son 100% exactas.